Piramal   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mumbai India (1988)
Status: No NME R&D (1988)

Organization Overview

First Clinical Trial
2005
NCT00407498
First Marketed Drug
1994
enflurane (ethrane)
First NDA Approval
2014
florbetaben F-18 (neuraceq)
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

LIFE MOLECULAR | Life Molecular Imaging GmbH | Nicholas Piramal Research Centre | Piramal Clinical Research (Hyderabad, India) | PIRAMAL CRITICAL | PIRAMAL ENT | Piramal Enterprises Limited | PIRAMAL HLTHCARE UK | Piramal Imaging GmbH | Piramal Imaging Limited | Piramal Imaging SA | Piramal Life Sciences | PIRAMAL PHARMA | Vice President- Clinical Research (R & D), Nicholas Piramal Research Centre | Wellquest Clinical Research

Active Ingredients

Marketed Drugs (21)

aprepitant (Emend) (2023)

baclofen (lioresal) (2010)

cinacalcet (sensipar) (2018)

cisatracurium (nimbex) (2020)

clobazam (onfi) (2018)

deferasirox (exjade) (2019)

dexmedetomidine (precedex) (2021)

enflurane (ethrane) (1994)

eplerenone (inspra) (2020)

florbetaben F-18 (neuraceq) (2014 NDA)

fluoxetine (prozac) (2022)

glycopyrronium (robinul) (2018)

isoflurane (forane) (1995)

levothyroxine (Synthroid) (2016)

lurasidone (latuda) (2020)

morphine (2018)

oxacillin (pathocil) (2017)

ranolazine (ranexa) (2023)

rocuronium (zemuron) (2019)

sevoflurane (ultane) (2007)

tetrabenazine (xenazine) (2020)

Drugs in Phase 4 Trials (2)

florbetaben F-18 (neuraceq) (6 trials)

mechlorethamine (mustargen) (1 trial)

Drugs in Phase 3 Trials (1)

nilotinib (tasigna) (1 trial)

Drugs in Phase 2 Trials (5)

68ga-rm2 (1 trial)

cisplatin (platinol) (1 trial)

gemcitabine (gemzar) (2 trials)

p2202 (1 trial)

riviciclib (11 trials)

Drugs in Phase 1 Trials (24)

18f-fluoromethyltyrosine (2 trials)

18f-fspg (1 trial)

18f-gp1 (1 trial)

[18f]pi-2620 (2 trials)

acetylsalicylic acid (aspirin) (2 trials)

bay1006578 (1 trial)

bay1075553 (1 trial)

bay94-9392 (2 trials)

bombesin (1 trial)

carboplatin (paraplatin) (1 trial)

fludeoxyglucose f-18 (1 trial)

mni-815 (1 trial)

naproxen (naprosyn) (2 trials)

olanzapine (zyprexa) (2 trials)

omeprazole (prilosec) (1 trial)

p11187 (1 trial)

p3914 (1 trial)

p7435 (2 trials)

pantoprazole (protonix) (2 trials)

panulisib (1 trial)

pl-225b (1 trial)

trandolapril (mavik) (2 trials)

vemurafenib (zelboraf) (1 trial)

voruciclib (4 trials)

Indications

Approved Indications


 

Alzheimer Disease

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 4)

Amyloidosis (Phase 2)

Aneurysm (Phase 1)

Aortic Aneurysm (Phase 1)

Aortic Aneurysm, Abdominal (Phase 1)

Brain Neoplasms (Phase 1)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cognitive Dysfunction (Phase 1)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Down Syndrome (Phase 2)

Duodenal Ulcer (Phase 1)

Head and Neck Neoplasms (Phase 2)

Inflammation (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Malnutrition (Phase 1)

Melanoma (Phase 2)

Mucositis (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 2)

Overweight (Phase 1)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Psoriasis (Phase 4)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Supranuclear Palsy, Progressive (Phase 1)

Syndrome (Phase 2)

Tauopathies (Phase 1)

Thrombosis (Phase 1)

Toothache (Phase 1)

Triple Negative Breast Neoplasms (Phase 1)

Venous Thrombosis (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 52
  • # of Trial APIs: 32